Data emerging on blood-based testing for colorectal cancer have prompted questions from gastroenterologists and public health experts. Upon the release of a recent study evaluating the sensitivity and specificity of one such test in development, an American Gastroenterological Association expert panel that was convened to add perspective underscored that such blood tests are not yet ready to usurp the role of established screening approaches.
The findings of the ECLIPSE trial on Guardant’s